# Robert Z. Orlowski

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/robert-z-orlowski/

## Facts

| Field | Value |
| --- | --- |
| Citations | 54,329 |
| Field | Multiple Myeloma Research and Treatments |
| h-index | 102 |
| i10-index | 397 |
| Last Known Institution | The University of Texas MD Anderson Cancer Center |
| OpenAlex ID | https://openalex.org/A5038235561 |
| ORCID iD | https://orcid.org/0000-0002-5723-4129 |
| Works | 1,166 |

## Researcher papers

- [International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma](https://scholariq.org/papers/international-myeloma-working-group-consensus-criteria-for-response-and-minimal/)
- [Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial](https://scholariq.org/papers/daratumumab-lenalidomide-bortezomib-and-dexamethasone-for-transplant-eligible/)
- [Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma](https://scholariq.org/papers/triplet-therapy-transplantation-and-maintenance-until-progression-in-myeloma/)
- [Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial](https://scholariq.org/papers/carfilzomib-or-bortezomib-in-combination-with-lenalidomide-and-dexamethasone-for/)
- [Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma](https://scholariq.org/papers/phase-i-study-of-cord-blood-derived-natural-killer-cells-combined-with/)
- [International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation](https://scholariq.org/papers/international-myeloma-working-group-guidelines-for-the-management-of-multiple/)

## Researcher topics

- [Multiple Myeloma Research and Treatments](https://scholariq.org/topics/multiple-myeloma-research-and-treatments/)
- [Protein Degradation and Inhibitors](https://scholariq.org/topics/protein-degradation-and-inhibitors/)
- [Ubiquitin and proteasome pathways](https://scholariq.org/topics/ubiquitin-and-proteasome-pathways-2/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)

## Researcher university

- [The University of Texas MD Anderson Cancer Center](https://scholariq.org/institutions/the-university-of-texas-md-anderson-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.